米氮平治疗抑郁症6个月随访研究  

Clinical Efficacy and Compliance of Mirtazapine in the Treatment of Depression

作　　者：陶明[1] 高静芳[1] 唐文新[1] 钱惠忠[1] 张萍[1] 周国岭[1] 焦静茹[1] 王家新[1] 叶建林[1] 任婉文[1] 张丽娜[1] 

机构地区：[1]杭州市第七人民医院,310013

出　　处：《中国心理卫生杂志》2004年第5期360-362,共3页Chinese Mental Health Journal

摘　　要：目的 :探讨新型抗抑郁药物米氮平的临床疗效及治疗依从性。方法 :采用Hamilton抑郁量表(HAMD)、Asberg抗抑郁剂副反应量表 (SERS)、临床总体印象量表 (CGI)和自编的治疗态度问卷 ,对 60例抑郁症患者在用米氮平进行 6个月的开放性治疗期间作了临床评估 ,并与 62例分别用氯丙咪嗪和氟西汀治疗的抑郁症患者进行对照。结果 :除门诊约定痊愈比例外 ,米氮平在起效时间、不良反应、处方依从、治疗态度、脱落情况等方面均具有显著的优势 (P <0 0 5 )。结论 :与传统三环类抗抑郁药相比 ,米氮平具有起效快、不良反应少、依从性好的特点。Objective:To investigate the clinical efficacy and compliance with a new antidepressant mirtazapine to treat depressive patients.Methods:A open-labeled study was conducted and followed up six months for 60 depressive patients treated with mirtazapine, 62 cases with depression, as a control group, treated with Clomipramine and Fluoxetine, which were assessed by Hamilton Depression Rating Scale(HAMD), Asberg Rating Scale for Side Effects(SERS), Clinical Global Impression(CGI) and Attitudes Questionaire made by ourselves. Results:The group treated with mirtazapine was superior to a control group in aspect of responsive time, early variety of factors in scales, side effects, prescription compliance , treatment attitudes and falling off cases(P<0.05), except for making clinical appointments and remission proportion.Conclusion:Mirtazapine is a better antidepressant with good clinical efficacy and compliance compared with other antidepressants.

关 键 词：精神病学 抑郁症 抗抑郁剂 米氮平 随访研究 治疗依从性 

分 类 号：R971.4[医药卫生—药品] R749.4[医药卫生—药学]